Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Life Sciences, Serologicals and AltaGen Biosciences, Evotec and ActivBiotics, Molecular Devices, Strategic Research Institute, and Tripos and EMBL-DKFZ Chemical Genomics Facility

Premium

Caliper to Release Q2 Financial Results; Hold Conference Call

Caliper Life Sciences said that it plans to release its second quarter financial results on Thursday, Aug. 5, at 8:00 a.m. EDT.

Caliper will hold a conference call and live webcast to discuss the results later that day, at 12:30 p.m. EDT.

The free webcast can be accessed at http://www.fulldisclosure.com or on the Caliper website, http://www.caliperLS.com. The company said a replay of the call will be available until Aug. 12, 2004.


Serologicals Completes Acquisition of AltaGen Biosciences

Serologicals said last week that it has completed the acquisition of AltaGen Biosciences and its subsidiary, Sierra BioSource. The acquisition was originally announced on June 30.

According to an official statement, the Sierra acquisition “enables Serologicals to more broadly address the cell culture market by providing custom research and development services and custom media formulation, as well as to accelerate its cell culture product development.”

Serologicals said it expected the acquisition to be accretive in fiscal year 2004. Additional financial details were not disclosed.


Evotec and ActivBiotics Forge Drug Discovery Agreement

Hamburg, Germany-based Evotec and Lexington, Mass.-based ActivBiotics announced last week that they have entered into a joint drug discovery project.

Under the terms of the agreement, Evotec will apply Evorationale, its rational drug design platform, to one of ActivBiotics’ anti-infective lead optimization programs.

The EVOrationale platform, according to the companies, provides de novo structure determination, validation of screening hits, and structure-guided lead optimization programs. Evotec said it has applied the platform to a range of drug targets, including kinases, GPCRs, proteases, enzymes, and complex protein-ligand interactions.

Financial terms of the deal were not disclosed.


Molecular Devices to Repurchase Shares

Molecular Devices’ board of directors has approved a plan for the company to repurchase up to an aggregate of 1.5 million shares of its common stock, the company said last week.

“Based on current market prices, we believe that our stock is undervalued and that the repurchase program is a good investment of available funds,” Joseph Keegan, MD’s president and CEO, said in an official statement.

MD said the repurchases will be made occasionally on the open market at prevailing market prices or in negotiated transactions off the market.


SRI to Hold Pharma & Biotech Business Intelligence Summit in September

The Strategic Research Institute announced that its fourth annual Pharma & Biotech Business Intelligence Summit will be held on Sept. 20 and 21 in Princeton, NJ, at the Westin Princeton at Forrestal Village.

The conference will be chaired by Daniel Pascheles, vice president and head of corporate CI for Aventis Pharma. SRI said that the conference promises presentations by an array of biotech and pharma industry leaders, and will tackle subjects including, but not limited to:

• Best practices and case studies on developing cost-effective and reliable intelligence

• Business intelligence in R&D strategy

• New techniques for effective pipeline assessment

• Aligning business intelligence with R&D initiatives and strategic business development

Further information on the conference can be found at http://www.srinstitute.com/cm243, by e-mail at [email protected], or by calling 1-888-666-8514.


EMBL-DKFZ Chemical Genomics Facility Taps Tripos for Lead Identification

Tripos has been selected by the European Molecular Biology Laboratory and the German Cancer Research Center to assist in the rapid identification of potential molecular leads, Tripos said.

Tripos, a drug-discovery chemistry and informatics company based in St. Louis, will use its technologies to facilitate rapid hit-finding, hit follow-up and chemical optimization of candidate molecules, the company said. Financial terms of the deal were not disclosed.

EMBL and DKFZ jointly established the Chemical Genomics Facility, one of the first European academic small-molecule screening facilities in Heidelberg, Germany.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.